Technical Analysis for JUNO - Juno Therapeutics, Inc.

Grade Last Price % Change Price Change
grade A 86.96 0.10% 0.09
JUNO closed up 0.1 percent on Monday, March 5, 2018, on 76 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Flat
See historical JUNO trend table...

Date Alert Name Type % Chg
Jan 23 New Uptrend Bullish 1.28%
Jan 23 Volume Surge Other 1.28%
Jan 23 Calm After Storm Range Contraction 1.28%
Jan 23 Narrow Range Bar Range Contraction 1.28%
Jan 23 NR7 Range Contraction 1.28%
Jan 23 NR7-2 Range Contraction 1.28%
Jan 23 Upper Bollinger Band Walk Strength 1.28%
Jan 23 Inside Day Range Contraction 1.28%
Jan 23 Wide Bands Range Expansion 1.28%
Jan 23 Above Upper BB Strength 1.28%

Older signals for JUNO ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. The company's additional product candidates comprise CD171, a cell-surface adhesion molecule to treat neuroblastoma; MUC-16, a protein for treating ovarian cancers; IL-12, a cytokine to overcome the inhibitory effects; ROR-1, a protein for the treatment of non-small cell lung, triple negative breast, pancreatic, and prostate cancers; and WT-1, an intracellular protein to treat adult myeloid leukemia and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers. It has license and collaboration agreements with Fred Hutchinson Cancer Research Center and Memorial Sloan Kettering Cancer Center; and license agreement with St. Jude Children's Research Hospital. The company was formerly known as FC Therapeutics, Inc. and changed its name to Juno Therapeutics, Inc. in October 2013. Juno Therapeutics, Inc. was founded in 2013 and is headquartered in Seattle, Washington.
Is JUNO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 87.01
52 Week Low 19.62
Average Volume 4,867,725
200-Day Moving Average 46.705
50-Day Moving Average 71.8614
20-Day Moving Average 86.094
10-Day Moving Average 86.534
Average True Range 0.9492
ADX 54.69
+DI 45.67
-DI 12.26
Chandelier Exit (Long, 3 ATRs ) 84.1624
Chandelier Exit (Short, 3 ATRs ) 87.6176
Upper Bollinger Band 87.3109
Lower Bollinger Band 84.8771
Percent B (%b) 0.86
BandWidth 2.82691
MACD Line 3.3713
MACD Signal Line 4.3489
MACD Histogram -0.9776
Fundamentals Value
Market Cap 9.13 Billion
Num Shares 105 Million
EPS -2.83
Price-to-Earnings (P/E) Ratio -30.73
Price-to-Sales 55.30
Price-to-Book 4.87
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 87.13
Resistance 3 (R3) 87.12 87.07 87.10
Resistance 2 (R2) 87.07 87.02 87.07 87.09
Resistance 1 (R1) 87.01 87.00 86.99 87.02 87.08
Pivot Point 86.96 86.96 86.94 86.96 86.96
Support 1 (S1) 86.90 86.91 86.88 86.91 86.84
Support 2 (S2) 86.85 86.89 86.85 86.83
Support 3 (S3) 86.79 86.85 86.82
Support 4 (S4) 86.80